Alzheimer’s Biomarker May Predict Early Onset

05:48 EST 10 Nov 2017 | Genetic Engineering News

Having the ability to detect diseases in their earliest stages of development is an invaluable therapeutic resource. For many diseases the initial onset times are when they are most vulnerable and therefore respond best to intervention modalities. However, symptoms at preliminary stages often go unnoticed or are dismissed as minor annoyances, delaying treatment. Thus, scientists are continually on the hunt for new biomarkers that could assist them with early detection. Now, researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) may have just uncovered a peptide that could lead to the early detection of Alzheimer's disease (AD).       The SBP researchers—publishing their findings today in Nature Communications “ Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer’s disease ”—believe their new results could provide a means of homing drugs to diseased areas of the brain to treat AD, Parkinson's disease, as well as glioblastoma, brain ...

Original Article: Alzheimer’s Biomarker May Predict Early Onset


More From BioPortfolio on "Alzheimer’s Biomarker May Predict Early Onset"

Quick Search


Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...